Payment overview · 2025
General Payments
$2,057.20
139 reported records · 22 companies
Healthcare provider profile · identity verified
Techsin T Ty, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KOKOMO, IN · NPI 1992705156
Verified facts
What the public records show
CMS Open Payments records show Techsin T Ty, MD received $2,057.20 in general payments during 2025 across 139 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nuplazid, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuplazid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 378 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.56 | 22.3% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.30 | 14.8% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $223.47 | 10.9% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $200.68 | 9.8% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.01 | 7.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.97 | 6.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.12 | 4.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.32 | 3.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.58 | 3.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.55 | 2.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.70 | 2.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.70 | 1.8% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $33.67 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.29 | 1.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $30.65 | 1.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.63 | 1.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.05 | 1.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.21 | 1.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.29 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.22 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.60 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,051.65 | 138 |
| Education | $5.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $308.01 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $223.47 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $212.71 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $183.06 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $157.46 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.68 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.68 | 11 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $131.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $98.90 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.12 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.65 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.05 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.05 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.84 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $68.72 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $68.72 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $61.58 | 4 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $61.58 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.97 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.97 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.24 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.70 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $33.67 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.07 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.56 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $5.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 378 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
378 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2154 | 212 |
| Gabapentin | Gabapentin | 1115 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 903 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 820 | 145 |
| Lisinopril | Lisinopril | 801 | 87 |
| Potassium Chloride | Potassium Chloride | 784 | 109 |
| Furosemide | Furosemide | 763 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 750 | 78 |
| Buspirone Hcl | Buspirone Hcl | 620 | 44 |
| Losartan Potassium | Losartan Potassium | 585 | 113 |
| Sertraline Hcl | Sertraline Hcl | 518 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 487 | 88 |
| Donepezil Hcl | Donepezil Hcl | 478 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 65 |
| Metformin Hcl | Metformin Hcl | 450 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 392 | 33 |
| Eliquis | Apixaban | 378 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 369 | 59 |
| Omeprazole | Omeprazole | 362 | 87 |
| Carvedilol | Carvedilol | 355 | 44 |
| Trazodone Hcl | Trazodone Hcl | 315 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 303 | 39 |
| Tramadol Hcl | Tramadol Hcl | 290 | 57 |
| Memantine Hcl | Memantine Hcl | 277 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 273 | 18 |
| Famotidine | Famotidine | 248 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 82 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 231 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 215 | 142 |
| Fluoxetine Hcl | Fluoxetine Hcl | 211 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 193 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 189 | 15 |
| Pregabalin | Pregabalin | 180 | 31 |
| Bupropion Xl | Bupropion Hcl | 164 | 31 |
| Montelukast Sodium | Montelukast Sodium | 157 | 43 |
| Topiramate | Topiramate | 157 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 156 | suppressed |
| Levetiracetam | Levetiracetam | 148 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 29 |
| Clonazepam | Clonazepam | 140 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 138 | suppressed |
| Xarelto | Rivaroxaban | 136 | suppressed |
| Allopurinol | Allopurinol | 133 | 19 |
| Risperidone | Risperidone | 127 | 16 |
| Farxiga | Dapagliflozin Propanediol | 126 | 24 |
| Jardiance | Empagliflozin | 122 | 23 |
| Simvastatin | Simvastatin | 121 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 25 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 116 | suppressed |
| Januvia | Sitagliptin Phosphate | 116 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 27 |
| Divalproex Sodium | Divalproex Sodium | 113 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 50 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 110 | suppressed |
| Ezetimibe | Ezetimibe | 108 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 105 | 21 |
| Glimepiride | Glimepiride | 104 | 25 |
| Meloxicam | Meloxicam | 102 | 25 |
| Spironolactone | Spironolactone | 102 | 18 |
| Clonidine Hcl | Clonidine Hcl | 97 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 45 |
| Lorazepam | Lorazepam | 97 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 28 |
| Methylprednisolone | Methylprednisolone | 96 | 72 |
| Mirtazapine | Mirtazapine | 94 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 94 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 23 |
| Alprazolam | Alprazolam | 92 | 25 |
| Cephalexin | Cephalexin | 91 | 47 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 87 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 27 |
| Sucralfate | Sucralfate | 85 | 22 |
| Baclofen | Baclofen | 84 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 12 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Movantik | Naloxegol Oxalate | 83 | suppressed |
| Trulicity | Dulaglutide | 83 | 20 |
| Olanzapine | Olanzapine | 82 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 78 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 78 | 20 |
| Midodrine Hcl | Midodrine Hcl | 75 | 13 |
| Lamotrigine | Lamotrigine | 74 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 32 |
| Lacosamide | Lacosamide | 67 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 66 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 21 |
| Alendronate Sodium | Alendronate Sodium | 64 | 20 |
| Nifedipine Er | Nifedipine | 63 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 63 | suppressed |
| Atenolol | Atenolol | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 11 |
| Diazepam | Diazepam | 59 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 45 |
| Torsemide | Torsemide | 57 | 13 |
| Brilinta | Ticagrelor | 54 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 17 |
| Cilostazol | Cilostazol | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 12 |
| Azithromycin | Azithromycin | 47 | 33 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Eszopiclone | Eszopiclone | 46 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Linzess | Linaclotide | 46 | 16 |
| Prednisone | Prednisone | 46 | 28 |
| Latanoprost | Latanoprost | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 12 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 31 |
| Lubiprostone | Lubiprostone | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 19 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 33 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Enulose | Lactulose | 35 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Colchicine | Colchicine | 34 | 11 |
| Estradiol | Estradiol | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Mesalamine | Mesalamine | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 25 |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Invokana | Canagliflozin | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 17 |
| Methadone Hcl | Methadone Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 13 |
| Primidone | Primidone | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 18 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Naproxen | Naproxen | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Buprenorphine | Buprenorphine | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Entecavir | Entecavir | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,057.20 · 139 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FASENRA, HETLIOZ, INGREZZA, JARDIANCE, KISUNLA, Kerendia, Korlym, LINZESS, LOREEV XR, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error